X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Glenmark Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS GLENMARK PHARMA DR. DATSONS LABS/
GLENMARK PHARMA
 
P/E (TTM) x -10.9 14.1 - View Chart
P/BV x 0.2 3.9 4.1% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 DR. DATSONS LABS   GLENMARK PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
GLENMARK PHARMA
Mar-16
DR. DATSONS LABS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1261,262 10.0%   
Low Rs31672 4.6%   
Sales per share (Unadj.) Rs133.0270.6 49.2%  
Earnings per share (Unadj.) Rs0.224.9 0.6%  
Cash flow per share (Unadj.) Rs6.634.4 19.2%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs128.8151.3 85.1%  
Shares outstanding (eoy) m31.66282.16 11.2%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.63.6 16.5%   
Avg P/E ratio x516.138.9 1,328.1%  
P/CF ratio (eoy) x11.828.1 42.2%  
Price / Book Value ratio x0.66.4 9.5%  
Dividend payout %08.0 0.0%   
Avg Mkt Cap Rs m2,477272,778 0.9%   
No. of employees `000NA10.0 0.0%   
Total wages/salary Rs m5613,782 0.4%   
Avg. sales/employee Rs ThNM7,614.9-  
Avg. wages/employee Rs ThNM1,374.8-  
Avg. net profit/employee Rs ThNM700.2-  
INCOME DATA
Net Sales Rs m4,21176,340 5.5%  
Other income Rs m79356 22.1%   
Total revenues Rs m4,28976,696 5.6%   
Gross profit Rs m56914,172 4.0%  
Depreciation Rs m2042,691 7.6%   
Interest Rs m4301,789 24.0%   
Profit before tax Rs m1310,048 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m63,028 0.2%   
Profit after tax Rs m57,019 0.1%  
Gross profit margin %13.518.6 72.7%  
Effective tax rate %48.030.1 159.4%   
Net profit margin %0.19.2 1.2%  
BALANCE SHEET DATA
Current assets Rs m6,85259,096 11.6%   
Current liabilities Rs m6,71140,018 16.8%   
Net working cap to sales %3.325.0 13.4%  
Current ratio x1.01.5 69.1%  
Inventory Days Days16175 214.6%  
Debtors Days Days318119 267.2%  
Net fixed assets Rs m3,67339,075 9.4%   
Share capital Rs m317282 112.2%   
"Free" reserves Rs m3,76130,281 12.4%   
Net worth Rs m4,07842,703 9.5%   
Long term debt Rs m1,67124,873 6.7%   
Total assets Rs m12,633111,026 11.4%  
Interest coverage x1.06.6 15.6%   
Debt to equity ratio x0.40.6 70.3%  
Sales to assets ratio x0.30.7 48.5%   
Return on assets %3.47.9 43.4%  
Return on equity %0.116.4 0.7%  
Return on capital %7.717.5 43.8%  
Exports to sales %22.943.3 52.9%   
Imports to sales %14.37.4 192.4%   
Exports (fob) Rs m96433,044 2.9%   
Imports (cif) Rs m6025,672 10.6%   
Fx inflow Rs m96436,945 2.6%   
Fx outflow Rs m60761,066 1.0%   
Net fx Rs m357-24,122 -1.5%   
CASH FLOW
From Operations Rs m1,3453,449 39.0%  
From Investments Rs m-2,256-8,802 25.6%  
From Financial Activity Rs m-1,2006,986 -17.2%  
Net Cashflow Rs m-2,111934 -226.0%  

Share Holding

Indian Promoters % 4.5 48.3 9.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 6.9 -  
FIIs % 1.4 34.4 3.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 10.5 896.2%  
Shareholders   20,807 56,727 36.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

Nov 8, 2016

Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

Glenmark: Other Income Boosts Profit Growth (Quarterly Results Update - Detailed)

Sep 6, 2016

Glenmark has announced its 1QFY17 results. The company has reported 15.8% YoY growth in net sales and 24% YoY increase in net profits. Here is our analysis of the results.

Securities & Intelligence Services Ltd. (IPO)

Jul 31, 2017

Should you subscribe to the IPO of Securities & Intelligence Services Ltd?

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 5-YR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS